**Virpax Pharmaceuticals Appoints Jay Panis to Board of Directors****

**

On December 17, 2024, Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) made a significant announcement regarding changes within its leadership structure. The Board of Directors appointed Mr. Jaydriane (Jay) Panis to the Board, filling the vacancy left by the resignation of Mr. Gary Herman.

Mr. Panis brings with him a wealth of experience in the financial services industry, boasting more than 20 years as a Certified Financial Planner (CFP). He is the founder of his own financial planning practice and currently serves as a director at a prominent Canadian financial planning firm headquartered in British Columbia. His educational background includes diplomas in Financial Management and Business Management, underpinning a successful career characterized by effective planning and leadership in helping clients achieve their financial objectives.

It’s been clarified that there are no preexisting arrangements or agreements involving Mr. Panis with any other party that influenced his selection as a director. Moreover, there are no transactions related to Mr. Panis that necessitate disclosure under Item 404(a) of Regulation S-K.

The decision to appoint Mr. Panis was rooted in the Board’s recognition of his robust expertise and proven track record in financial management. The Board anticipates that his insights and leadership in this realm will prove valuable in driving strategic decisions for the company moving forward.

In line with this development, Virpax Pharmaceuticals filed the requisite Form 8-K with the Securities and Exchange Commission, with the company emphasizing its compliance with regulatory obligations and commitment to transparent disclosure practices.

Investors and industry stakeholders are keenly watching to see how the addition of Mr. Panis to the Board will impact the strategic direction and operational dynamics of Virpax Pharmaceuticals in the upcoming quarters.

As per the filing, no further material information or disclosures regarding this appointment were made apart from the details outlined above.

The company included the Cover Page Interactive Data File (embedded within the Inline XBRL document) as part of its submission to the SEC in accordance with reporting requirements.

Virpax Pharmaceuticals remains dedicated to upholding high standards of corporate governance and keeping its shareholders informed about key developments within the organization.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Virpax Pharmaceuticals’s 8K filing here.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.